Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab in Marginalzone Lymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

NCT04268277 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT04268277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04268277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab in Marginalzone Lymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2022
Completion date
December 6, 2024
Enrollment
22 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma